COVID-19 Vaccine Development
  • Biopharmaceutical Development on COVID:19

COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments.  The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa

The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness

 

Committee Members
Speaker at Drug Delivery Events - Vladlen Slepak

Vladlen Slepak

University of Miami Miller School of Medicine, United States
Speaker at Drug Delivery Events - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Pharmaceutical Conference - Consolato M Sergi

Consolato M Sergi

Universities of Alberta and Ottawa, Canada
Speaker at Drug Delivery Events - Huiqin Yang

Huiqin Yang

ICON Clinical Research Ltd, United Kingdom

Submit your abstract Today

Youtube
Watsapp